Country: Canada
Language: English
Source: Health Canada
FLUOROURACIL; SALICYLIC ACID
CIPHER PHARMACEUTICALS INC
L01BC52
FLUOROURACIL, COMBINATIONS
0.5%; 10%
SOLUTION
FLUOROURACIL 0.5%; SALICYLIC ACID 10%
TOPICAL
25ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0255930001; AHFS:
APPROVED
2015-08-27
_ _ _ACTIKERALL Product Monograph _ _Page 1 of 26_ PRODUCT MONOGRAPH PR ACTIKERALL TM fluorouracil and salicylic acid Solution (0.5%/10%) Topical Antineoplastic Agent Cipher Pharmaceuticals Inc. 2345 Argentia Road, Unit 100A Mississauga, ON L5N 8K4 Date of Preparation: August 7, 2015 Submission Control No: 185418 _ _ _ACTIKERALL Product Monograph _ _Page 2 of 26_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................9 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY ..........................................................................................13 SPECIAL HANDLING INSTRUCTIONS .......................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFORMATION ..........................................................................15 CLINICAL TRIALS ............... Read the complete document